Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

| More on:
Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index (ASX: XJO) healthcare stock Telix Pharmaceuticals Ltd (ASX: TLX) has delivered some smashing returns to shareholders, both over the short and long term.

And it looks well-placed to continue outperforming.

Shares in the diagnostic and therapeutic product developer have gained a whopping 135% since this time last year.

Longer term, the ASX 200 healthcare stock is now up 339% in two years.

Shorter term, the Telix Pharmaceuticals share price leapt 19.2% in January.

And this made Telix shares one of the "stand-out contributors" in January for the Monash Investors Small Companies Fund.

ASX 200 healthcare stock on the growth path

"Telix has been a long held holding for the fund and is a top holding." Monash Investors noted in the fund's January investor update. "The company had an eventful January with a number of positive developments helping drive its shares up 19% to contribute 1% to performance."

Commenting on those positive developments for the ASX 200 healthcare stock, the fund managers said:

First, it announced the acquisition of a bundle of next-gen therapeutic candidates, a biologics tech platform, and research facility, further building out its drug pipeline and innovation capabilities. It also completed its previously announced acquisition of a radiopharmacy network.

It announced the European approval of its principal product, prostate imaging agent Illuccix. This is an important milestone in along the pathway to full global commercialisation of this product.

Monash Investors also pointed to the company's strong revenue growth for driving the Telix Pharmaceuticals share price higher once more in January.

"These fundamental developments were topped off with a revenue announcement ahead of prior guidance," the fund managers said.

After market close on 13 January, the company announced that it had achieved total unaudited full-year revenue of around US$517 million (AU$783 million), up 55% year on year. That handily beat the ASX 200 healthcare stock's full-year revenue guidance range of US$490 million to US$510 million.

Looking ahead, Monash Investors concluded, "Telix continues its global growth journey and remains on track to become a truly great Australian success."

What's the latest from Telix Pharmaceuticals?

This morning, the ASX 200 healthcare stock reported on further global market penetration with its principal product, prostate imaging agent Illuccix.

Telix announced that the United Kingdom Medicines and Healthcare Products Regulatory Agency has approved the Marketing Authorisation Application for Illuccix.

According to the release, Illuccix is indicated in the UK for the detection and localisation of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET (positron emission tomography).

Commenting on the UK approval, Telix Pharmaceuticals CEO Raphael Ortiz said:

PSMA-PET imaging is one of the most important developments in prostate cancer detection in recent years, and we are delighted that we can now bring Illuccix to physicians and their patients across the UK.

Should you invest $1,000 in Uber Technologies right now?

Before you buy Uber Technologies shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Uber Technologies wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should you buy the dip on the CSL share price?

Has the market sell-off created an opportunity to buy this mega ASX 200 blue chip at an attractive price?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 136% in a year, why is this ASX 200 share slipping on Wednesday?

The high-performing ASX 200 share is expanding its product pipeline.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Meet the dirt cheap ASX 200 stock that could rocket 75%

Bell Potter thinks investors should be snapping up this stock while it is down in the dumps.

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

This ASX 200 healthcare share is sinking 9% on CEO exit

Investors are selling off this stock on Tuesday. Here's what you need to know.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why is the CSL share price falling on Monday?

The ASX 200 biotech stock has lost 9% of its value since the start of the new year.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are Sonic Healthcare or CSL shares a better buy?

Which of these healthcare giants is a better buy?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Dividend Investing

Hoping to bag the boosted dividend from CSL shares? Here's your deadline…

The ASX 200 biotech is rewarding investors with a 9% higher interim dividend this year.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

2 ASX healthcare shares rated as top buys

Are these two names healthy choices for your portfolio? Let's see.

Read more »